Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.61 |
| ▸ | CCR2 | P41597 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | DBH | P09172 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1607395 | 0.85 | CNR2 (0.57) | KDM4ECCR2ADRA1DEPHX2SMN1; SMN2 | |
| SCHEMBL8942396 | 0.84 | VEGFA (0.57) | KDM4EEGLN1CCR2RECQLEPHX2 | |
| SCHEMBL7192423 | 0.84 | KDM4E (0.67) | KDM4EEGLN1CCR2RECQLADRA1D | |
| SCHEMBL25392998 | 0.83 | KDM4E (0.71) | KDM4EEGLN1RECQLEPHX2KMT2A | |
| SCHEMBL21525516 | 0.82 | KDM4E (0.54) | KDM4EEPHX2ALDH1A1DBHMAPT | |
| SCHEMBL25392383 | 0.82 | KDM4E (0.54) | KDM4EEPHX2SMN1; SMN2PPARACNR2 | |
| SCHEMBL12926197 | 0.82 | KDM4E (0.54) | KDM4ERECQLADRA1DEPHX2ALDH1A1 | |
| SCHEMBL3349244 | 0.81 | EGLN1 (0.68) | KDM4EEGLN1RECQLKMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6919162 | 0.80 | EGLN1 (0.67) | KDM4EEGLN1RECQLKMT2ASMN1; SMN2 | |
| SCHEMBL5035573 | 0.78 | LPO (0.57) | KDM4ECCR2ADRA1DKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | disclosed |
| US-11464838-B2 | Optimized cancer stem cell vaccines | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2022-10-11 | — | — | US | disclosed |
| US-8969340-B2 | Methods for treating chronic pelvic pain syndrome | NORTHWESTERN UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969340-B2 | Methods for treating chronic pelvic pain syndrome | NORTHWESTERN UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130303530-A1 | METHODS FOR TREATING CHRONIC PELVIC PAIN SYNDROME WITH ANTIBODIES THAT BINDS MCP-1 OR MIP-1A | NORTHWESTERN UNIVERSITY (US) | 2013-11-14 | — | — | US | disclosed |
| US-20110014205-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC PELVIC PAIN SYNDROME | MOMENTIVE PERFORMANCE MATERIALS INC. | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303530-A1 | METHODS FOR TREATING CHRONIC PELVIC PAIN SYNDROME WITH ANTIBODIES THAT BINDS MCP-1 OR MIP-1A | CCR1, CCR2, CCL2 | KDM4E 4479/4885EGLN1 1548/4885CCR2 2/4885 |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | KDM4E 4706/4885EGLN1 3239/4885CCR2 4822/4885 |
| US-20110014205-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC PELVIC PAIN SYNDROME | CCR2, CCR1, CCL2 | KDM4E 4614/4885EGLN1 754/4885CCR2 1/4885 |
| US-11464838-B2 | Optimized cancer stem cell vaccines | CD44, TP53, TSG101 | KDM4E 3127/4885EGLN1 1133/4885CCR2 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.